Most material SEC filings — August 24, 2026

Expion360 Inc. executed a Securities Purchase Agreement dated August 21, 2026, to issue up to $9,000,000 in principal amount of 8% Convertible Debentures due August 21, 2029, plus Common Stock Purchase Warrants. Upon shareholder approval and filing of Certificate of Designation, debentures convert automatically into Series A-1 8% Convertible Preferred Stock (up to 9,000 shares at $1,000 stated value per share). Warrants exercise at $4.25 per share; conversion price for preferred stock also $4.25. Transaction includes registration rights and anti-dilution protections.

As of August 23, 2026, Bitmine holds 5,847,611 ETH tokens (valued at ~$14.2B at $2,440/token), 210 Bitcoin, $308M cash/marketable securities, $180M Beast Industries stake, and $89M Eightco stake, totaling $14.9B. This represents 4.8% of the 120.7M total ETH supply. The company has staked 5,067,309 ETH (~87% of holdings) through its MAVAN platform, generating projected annualized staking revenues of $330M–$381M at full scale.

On August 21, 2026, Northann Corp. (market cap ~$2.3M) received notice of potential delisting or failure to satisfy continued listing standards. The filing indicates Item 3.01 was triggered, relating to delisting risk or transfer of listing. No specific remedy period, listing exchange details, or financial metrics triggering the notice are disclosed in this 8-K excerpt.

On August 21, 2026, Senmiao Technology Ltd received a notice of delisting or failure to satisfy continued listing standards (Item 3.01). No specific listing rule violations, remediation timeline, or exchange details are disclosed in the filing text provided. This represents a critical corporate development for a $4.8M market-cap company.

LAO Professionals resigned as Northann Corp.'s independent auditor on June 8, 2026, after discovering their firm name and audit opinion were used without authorization in the Company's 2025 Form 10-K (filed April 14, 2026). The auditor stated it could not complete audit procedures due to the Company's repeated refusal to provide accessible documents, instead sending only inaccessible links, preventing verification of financial statements. This represents a complete breakdown of the audit relationship and a severe red flag regarding financial statement reliability for a $2.3M market-cap company.

Bio-Techne Corporation (market cap ~$11.4B) has entered into an Agreement and Plan of Merger with Merck KGaA, Darmstadt, Germany and EMD Holdings NewCo, Inc. (Merger Sub), whereby Merger Sub will merge with Bio-Techne, with Bio-Techne surviving as a wholly-owned subsidiary of Merck. The filing includes retention agreements effective June 23, 2026, conditioning employee retention bonuses (amounts blank in template) on continued employment through closing or qualifying terminations, with Section 280G gross-up protection and restrictive covenants. No purchase price, financing terms, timeline, or deal value disclosed in exhibits filed.

Pantages Capital Acquisition Corp (a blank-check SPAC with ~$29.4M in assets) filed an 8-K on August 24, 2026, disclosing notice of delisting or failure to satisfy continued listing standards. The filing cites Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing) but provides no specific details on which exchange rule was breached, remediation timeline, or the underlying cause.

RE/MAX Holdings filed an 8-K on 2026-08-24 indicating Item 3.01 (delisting/listing standard failure), Item 2.01 (acquisition completion), Item 5.01 (change in control), Item 1.02 (material agreement termination), and Items 3.02-3.03 (equity issuance and security holder rights modifications). The filing does not disclose specific dollar amounts, counterparties, share counts, or transaction details in the header; the actual substantive disclosures are in the attached document (tm2623567d10_8k.htm), which is not provided in full text here.

Weatherford International and NCS Multistage announced August 31, 2026 at 5:00 P.M. ET as the deadline for NCS Multistage stockholders to elect merger consideration: either 0.554 Weatherford shares per NCS share, or 0.239 Weatherford shares plus cash equivalent to 0.137 Weatherford shares, subject to proration. Transaction expected to close September 1, 2026, and has been approved by both boards and NCS Multistage's controlling stockholder (>50% owner). Until closing, the companies remain separate and independent.

Polar Power (market cap ~$3M) filed an S-1 on August 24, 2026 registering up to 8,488,774 shares (201.6% of outstanding) for resale by five selling stockholders. Securities include convertible notes: CFI Capital $600K (1.2M shares), Monroe Street $370.6K (1M shares), Mayers $275K (764K shares); Series A Preferred (1,611 shares, convertible to ~4.9M common); and warrants (537,696 shares). Company faces critical Nasdaq compliance: received deficiency notice May 1, 2026 for falling below $2.5M stockholders' equity (had ~$0.1M); received extension to October 28, 2026 to cure or face delisting. Company is insolvent (going-concern doubt noted by auditors) and restructuring.

BioXcel Therapeutics amended its April 2022 Credit Agreement with Oaktree Fund Administration (administrative agent) and lenders. The amendment requires the company to enter definitive agreements for either: (A) full cash repayment of all loan obligations by August 28, 2026, or (B) an alternative capital solutions transaction acceptable to Majority Lenders. The company must also cooperate in good faith with lenders regarding regulatory processes affecting material assets through that same date.

Ocean Power Technologies revised its FY2026 (ended April 30, 2026) preliminary results after audit completion: revenue decreased $0.4M (from $4.1M to $3.7M), gross loss improved by $2.2M (from −$8.1M to −$5.9M), but net loss worsened by $5.2M (from −$43.7M to −$48.9M) due to accounting treatment changes for revenue, costs, and a $5.7M fair-value loss on a financial instrument. Additionally, auditors included a going-concern qualification in the Form 10-K, indicating substantial doubt about the company's ability to continue operations. The revisions do not affect cash, cash flows, or customer contracts.

New Concept Energy filed an 8-K reporting Item 3.02 (unregistered equity sales), Item 5.01 (change of control), and Item 5.07 (shareholder vote submission) effective August 21, 2026. The filing does not disclose specific dollar amounts, share counts, counterparties, or transaction terms in the accessible header/metadata; full details require reviewing the complete 8-K document text.

10% owner CASCADE INVESTMENT, L.L.C. (RSG) bought 400K shares (~$88.2M) on the open market (0.4% of holdings). Open-market insider purchase — historically a bullish signal.

10% owner Blackstone Holdings IV L.P. (NONE) bought 770K shares (~$20.1M) on the open market (99% of holdings). Open-market insider purchase — historically a bullish signal.

On August 21, 2026, Serina Therapeutics (clinical-stage biotech, market cap ~$21.8M) entered a Common Stock Purchase Agreement with Roth Principal Investments, LLC granting Serina the right to sell up to $25,000,000 of common stock over 36 months at VWAP-based prices (7–3% discount tiered). Up to 12,500,000 shares may be issued, representing ~33% dilution if fully drawn. Serina is not obligated to sell, and the timing/amount are entirely discretionary. No proceeds received yet; agreement effective August 21, 2026.

Jorey Chernett, beneficial owner of >5.5% of CVRx shares via Pointillist Family Office, delivered August 24, 2026 letter to the Board demanding immediate strategic sale process, citing Barostim's value to large medical device acquirers and urging cost cuts pending review. Chernett acquired 405,000 shares on 08/07/2026 at $2.70/share (~$1.09M) and sold 18,574 shares total in prior transactions; current shareholding represents ~$312M notional value at recent trading prices, material to company's $112.4M market cap.

Comstock closed the sale of 100% of its mining subsidiaries (Comstock Mining LLC, Processing LLC, Exploration LLC, Real Estate Inc.) and all related assets to Mackay Precious Metals Inc. (subsidiary of Mackay Gold Silver Corp.) for aggregate consideration valued at >$45M: $20M cash received plus 2M Mackay shares (~$4.5M), with $7M due in 18 months. Comstock expects to record a $10M–$12M non-taxable gain, retains 1.5% NSR royalty on precious metals/minerals, has contingent $10M payment if Mackay constructs mine or achieves $500M+ sale within 7 years, and projects $1.5M annual operating cost savings.

On August 19, 2026, U.S. District Judge Stephen V. Wilson modified a 2020 consent decree governing the CA-324 and CA-325 onshore pipelines (acquired by Sable in February 2024). The court relieved original defendant Plains All American Pipeline of ongoing obligations, transferred regulatory authority from California's OSFM to federal PHMSA, and incorporated California state pipeline safety standards into the decree itself. Sable restarted the pipelines on March 14, 2026 (after a DPA order from Energy Secretary Chris Wright on March 13, 2026) without required state approval, violating the consent decree. The court imposed $1.449 million in stipulated penalties ($2,000–$5,500/day for 159 days across two pipelines) but denied an injunction since PHMSA now has authority. The court upheld the DPA order's preemption of California state law and trespass claims, and remanded a state-court preliminary injunction case back to state court on timeliness grounds.

KLX Energy Services Holdings, Inc. registered a transferable rights offering on August 24, 2026, under Form S-3. Eligible holders (common shareholders and warrant holders as of August 21, 2026 record date) receive 1 subscription right per share/warrant. Each right purchases 3.885 common shares at $1.49/share, totaling up to 83,876,809 shares issuable. Rights trade on Nasdaq under symbol KLXER through September 23, 2026 expiration. Over-subscription privilege available; 9.995% ownership cap enforced. Computershare serves as subscription agent.

Precision BioSciences announced first patient dosing in August 2026 in the Phase 1/2 FUNCTION-DMD clinical trial of PBGENE-DMD, an in vivo gene-editing therapy for Duchenne muscular dystrophy. The trial targets ambulatory DMD patients aged 2–7 with exons 45–55 mutations (affecting ~60% of DMD patients); first site was Arkansas Children's Hospital. Initial safety data expected by year-end 2026. No financial figures, partnership amounts, or share issuances disclosed in this filing.

Soluna completed acquisition of 397 acres in Briscoe County, Texas (exceeding the originally planned 300 acres) for Project Dorothy 3, a planned 300 MW renewable-first AI computing campus. The land sits adjacent to Soluna's existing Projects Dorothy 1 and 2 and the 150 MW Briscoe Wind Farm acquired in April 2026, enabling direct behind-the-meter access to owned generation. The purchase price was not disclosed in the filing.

John Marotta resigned as CEO and director of Azenta, Inc. (market cap ~$1.0B). Dr. Martin Madaus, a current board member who joined in 2024 with 30+ years in diagnostics/life sciences and prior CEO roles at Millipore, Ortho-Clinical Diagnostics, and Roche Diagnostics North America, was appointed interim President and CEO. The company reaffirmed Q4 FY2026 revenue guidance but now expects a one-time ~$3 million consulting expense to impact adjusted EBITDA in Q4; excluding this charge, adjusted EBITDA guidance remains unchanged. Heidrick Struggles has been retained to conduct a permanent CEO search.

USA Rare Earth announced completion of a $1.55 billion capitalization of a special purpose vehicle (SPV) to acquire Serra Verde's rare earth mining and processing operations in Brazil. The U.S. Department of War committed $750 million (upsized from $500 million), a Tier-1 bank provided a $500 million senior debt commitment letter, and the DoW entered a forward purchase contract for $300 million of rare earth products over five years. The Serra Verde merger is expected to close promptly following the August 28, 2026 stockholder vote, conditional on standard closing requirements.

Silver Bow Mining Corp. and subsidiary Silver Bow Tunnels Corp. are acquiring substantially all assets of Montana Tunnels Mining Inc. (MTMI) and Montana Goldfields Inc. (MTGF) comprising the Montana Tunnels Mine and Diamond Hill Mill in Montana. The deal includes two closings: (1) First Closing upon bankruptcy court approval—SBMT funds MTMI creditor claims (~$25.5M per Schedule VII) via escrow; (2) Final Closing—SBMT issues 3.5M final CVRs + 11.5M deferred CVRs (15M total, convertible to SBMT shares), executes toll-milling, NSR, and water-rights agreements. SBMT must commit $5M to M-Pit feasibility study within 60 days and $3M to Clancy Creek permitting within 6 months post-closing. Outside date: November 30, 2026.

Tenon Medical received written notice on August 24, 2026, from Nasdaq confirming it regained compliance with the minimum $1.00 bid price requirement. The company executed a 1-for-35 reverse stock split effective August 10, 2026, and maintained bid prices at or above $1.00 for 10 consecutive business days (August 10–21, 2026), resolving a deficiency notice dated February 25, 2026.

GridAI Technologies (market cap ~$14.9M) completed three private placements May–July 2026: $2.54M (May 8–12), $5.25M (May 11), and $8.5M (July 1), totaling $16.29M gross proceeds. Company received only $4M upfront; remaining $12.3M contingent on S-1 effectiveness by Jan 2027. Offerings included 270,192 common shares, 4.68M pre-funded warrants ($0.00001 exercise), and 4.95M common warrants ($2.56–$4.47 exercise). If all warrants exercised in cash, existing shareholders diluted to ~42.5%; on cashless exercise (VWAP $3.83), dilution to ~56.2%. Company recognized $10.1M goodwill impairment in Q2 2026 on Grid AI unit; $1.4M cash on hand; $7.8M annual burn; 18-month runway if S-1 effective. Auditors express substantial doubt on going concern.

On August 21, 2026, Skye Bioscience entered an Equity Purchase Agreement with Redmile Biopharma Investments III, L.P. for up to $22,000,000 in common and non-voting shares via monthly purchase notices (max $2M/month), plus a warrant to purchase ~$5M worth of shares (amount divided by PIPE price). Redmile becomes a ~10% beneficial owner cap holder with registration rights; shares priced at lower of PIPE price or market price (minimum 90% of PIPE price). The facility terminates on the third anniversary of closing or upon earlier qualifying events (change of control, other equity raise exceeding available amount, funded PIPE reaching $125M+).

Silver Bow Mining signed a definitive agreement to acquire the Jefferson County Metallurgical Complex (a 15,000-tpd flotation plant and 1,000-tpd gold mill near Butte, Montana) through a Chapter 11 sale of Montana Tunnels Mining Inc. Initial Closing (~Sept 8, 2026) requires ~$28.6M cash to settle obligations ($4.27M to Jefferson County, $20.8M to Montana DEQ). Final Closing involves issuing 3.5M CVRs (convertible to common shares 180 days later) plus 11.5M deferred CVRs tied to M-Pit feasibility and production milestones. The company commits $5M to complete an M-Pit feasibility study and $3M for Clancy Creek permitting/engineering. The facility has a stated replacement value of ~$350M.

On August 6, 2026, ACRES Commercial Realty Corp. (market cap ~$106M) completed an internalization merger with ACRES Capital Corp., acquiring the external manager. ACR issued approximately 7.5 million shares (exchange ratio 2.61882 per ACC share) valued at ~$109M based on closing price of $14.60/share. Preliminary purchase price: $68.9M with $169.5M goodwill recognized. Post-combination costs estimated at ~$39.5M including $13.7M stock option fair value and $23.8M payroll taxes. Pro forma weighted average shares increased from 6.6M to 13.4M (6-month period); pro forma net loss for H1 2026: $(36.9)M vs. historical ACR loss of $(13.5)M.

Backblaze, Inc. executed an indenture dated August 24, 2026 with U.S. Bank Trust Company for 0.00% Convertible Senior Notes due August 15, 2031, with initial aggregate principal amount of $201,250,000. Notes are convertible at 45.5705 shares per $1,000 principal (initial conversion price ~$21.96). Settlement at conversion is via cash, stock, or combination thereof at company's election.

On August 13, 2026, NextNRG issued 1,000,000 shares of Series C Preferred Stock to NX Energy SPV LLC for $9.2M (partially funded by canceling a $2M convertible note). The Series C converts into up to 112.9M common shares at a $0.75 conversion price with a $0.135 floor, accrues 12.5% annual dividends compounded monthly, and carries mandatory redemption at 125% of stated value plus dividends on default. The deal also permits up to 2M additional shares issuable for $18M more under conditions. With 168.1M shares currently outstanding, conversion would add 67% more shares, heavily diluting existing holders.

On August 21, 2026, Change Agents Corporation amended its July 22, 2026 equity purchase agreement with Hudson Global Ventures, LLC. Key changes: (1) Purchase Price reduced from $0.30 to $0.20 per share; (2) Minimum pricing threshold lowered from $0.41 to $0.30 per share; (3) Applicable Trading Amount (put option values) ranges from $15,000 to $500,000 depending on stock price performance; (4) Added 19.99% cap on share issuance without stockholder approval per Nasdaq Rule 5635(d). The amendment materially weakens the company's negotiating position and increases dilution risk.

Greenland Mines Ltd. entered into a Sales Agreement with A.G.P./Alliance Global Partners on August 24, 2026, authorizing the sale of up to $50 million in common stock through an at-the-market offering under a shelf registration statement (File No. 333-288533, effective July 17, 2025). The company will issue shares at market prices through the sales agent, paying a commission to be specified in individual placement notices. No specific share count or pricing floor is stated in this agreement; terms vary by placement notice.

FDA placed a clinical hold on RGX-121 (clemidsogene lanparvovec) for MPS II following discovery of asymptomatic spine MRI findings in five participants in the CAMPSIITE study conducted 3–6 years prior. REGENXBIO does not expect to resubmit the BLA in the near term. The company is shifting focus to its Duchenne (RGX-202) and retinal disease (wet AMD) programs, with planned Duchenne BLA submission this quarter and wet AMD topline data in Q4 2026.

Star Equity Fund LP, holding 6,285,065 shares (approximately 34.7% of GEE Group), withdrew its June 2026 proxy contest and director nomination on August 21, 2026. In exchange, GEE Group committed to declassify its board structure by the 2027 Annual Meeting so a majority serves one-year terms. Star Equity is restricted by standstill provisions until approximately one year after the 2026 Annual Meeting, capped at 7.5% ownership growth, and must vote with board recommendations except on extraordinary transactions. GEE Group will reimburse Star Equity $50,000 in legal expenses.

3i, LP converted 2,020,404 shares of Series C Preferred Stock at $0.39/share (≈$788k) on 08-20-2026, then sold 443,361 common shares over three days (08-20 to 08-24-2026) at prices ranging $0.1143–$0.1763, realizing ≈$64k gross. This represents a shareholder converting a large preferred position and immediately liquidating common stock at significantly lower prices than conversion cost.

Between July 27 and August 24, 2026, D.E. Shaw Co. entities (via Cogence and Valence Portfolios) systematically sold 4,761,689 shares of Gossamer Bio at prices ranging from $0.1434 to $0.2522 per share, totaling approximately $736M in gross proceeds (unaudited). The sales occurred across 44 separate transactions over 19 trading days. This represents a substantial reduction in D.E. Shaw's stake and signals activist selling pressure or liquidity event.

Callan JMB Inc. (via subsidiary Callan Power LLC) agreed to acquire Reger Oil's Williston Basin oil and gas portfolio (26 Montana leases, ~8,000 acres) for $10M in Series A Perpetual Convertible Preferred Stock (1,000 shares at $10,000 stated value each) plus $2M cash (due by Dec 31, 2026). Michael Reger becomes President of Buyer and joins Callan's board. Closing scheduled for Sept 22, 2026. Reger retains certain liabilities; Buyer assumes production obligations under existing Chandler Energy development agreement.

In a patent infringement lawsuit brought by Beckman Coulter, Inc. in U.S. District Court for Delaware, a jury found in Cytek's favor on three of four asserted claims (noninfringement and invalidity). However, the jury found infringement under the doctrine of equivalents on one claim and awarded damages of $20 million in lost profits plus $36 million in royalties (total $56 million). Cytek states it will challenge the single adverse finding and damages award via post-verdict motions and potentially appeal to the Federal Circuit.

Director Arkin Moshe (ODYS) bought 1.1M shares (~$3.6M) on the open market (22% of holdings). Open-market insider purchase — historically a bullish signal.

On August 20, 2026, Presidio Property Trust completed a five-year lease extension with Johns Hopkins University (Bloomberg School of Public Health), its largest tenant occupying all 31,752 sq ft of the Baltimore property. The lease now extends to December 31, 2031. No financial terms (rent, rate changes) or property valuation are disclosed.

Director Courtis Kenneth S. (AMR) bought 15K shares (~$3.2M) on the open market (1.5% of holdings). Open-market insider purchase — historically a bullish signal.

10% owner Blackstone Holdings IV L.P. (NONE) bought 273K shares (~$7.1M) on the open market (90% of holdings). Open-market insider purchase — historically a bullish signal.

On August 21, 2026, Tianci Group Holding Limited (a wholly-owned subsidiary of NASDAQ-listed Tianci International Inc) entered into an Equipment Procurement Agreement with McQueen Tech Co., Limited to purchase 125 units of Bitmain S21 XP mining equipment for USD $500,000 total ($4,000 per unit). Payment terms: 50% ($250,000) due within 10 days of signing; remaining 50% due within 3 days after delivery acceptance. The agreement covers equipment procurement, warranty via Bitmain's manufacturer policy, and advisory services for mining operations and hosting location identification.

President and CEO WILSON TROY EDWARD (KURA) bought 100K shares (~$1.2M) on the open market (17% of holdings). Open-market insider purchase — historically a bullish signal.

10% owner ADAR1 Capital Management, LLC (TENX) bought 1.0M shares (~$1.8M) on the open market (17% of holdings). Open-market insider purchase — historically a bullish signal.

BioCardia announced on August 24, 2026 that the FDA has confirmed and finalized meeting minutes from a May 2026 pre-submission meeting regarding the Helix Transendocardial Delivery Catheter System. The company intends to submit a follow-on pre-submission this quarter with the goal of obtaining De Novo pathway approval. No dollar amounts, equity dilution, or specific timelines for FDA decision were disclosed in this announcement.

Evolution Metals Technologies Corp. (EMAT) announced preliminary inclusion in the Russell 2000 Index and Russell 3000 Index, effective September 21, 2026, subject to FTSE Russell's standard review process. No specific dollar amounts or share counts changed in this announcement; the filing documents a capital markets milestone that broadens visibility to institutional and index-oriented investors tracking ~$12.2 trillion in benchmarked assets. The company is simultaneously expanding rare earth magnet production capacity to ~10,000 metric tons annually by November 2026 through binding purchase orders for thirteen ULVAC production machines.

Booz Allen Hamilton completed its acquisition of Ultra I C Mission Solutions business for $720 million on August 24, 2026. The deal combines Ultra's defense technology software, encryption, and edge-compute products with Booz Allen's AI-driven battle management and resilient communications capabilities. Ultra Mission Solutions will operate as a standalone commercial product and solutions component within Booz Allen's defense technology business, led by president Steve Escaravage.